New drug combo aims to tame myeloma in older patients without harsh chemo
NCT ID NCT04151667
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase II study tests a treatment plan using daratumumab (Darzalex) and dexamethasone for adults aged 65 and older with newly diagnosed multiple myeloma who cannot handle intensive chemotherapy. The goal is to see how well the combination controls the disease by measuring response rates. Thirty-three participants receive the drugs over several months, with the hope of offering a gentler yet effective option.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Daratumumab (Darzalex) and dexamethasone
- What this could lead to
- If successful, this could offer an effective treatment option for older adults with multiple myeloma who cannot tolerate intensive chemotherapy, potentially controlling the disease for longer.
- What could go wrong
- This is a small Phase II study with only 33 participants, so results may not apply to all patients. The treatment may not work as well as hoped, and side effects like infections or allergic reactions are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
H. Lee Moffitt Cancer & Research Institute
Tampa, Florida, 33612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- A guided path back to work after blood cancer: a trial tests the impact